Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr ...

On Tuesday, the U.S. Food and Drug Administration (FDA) placed a clinical hold on Atara Biotherapeutics, Inc.’s (NASDAQ:ATRA) ...

Atara Biotherapeutics has just announced a CRL by FDA for EBVALLO. Click here to read more about ATRA stock and why it is ...

The share price of Atara Biotherapeutics Inc. began a slow climb up after the company experienced a steep drop earlier this month. The Thousand Oaks drug ...

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or "the Company") for ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Iovance Biotherapeutics (IOVA – Research Report) and ...

HC Wainwright issued their FY2024 EPS estimates for Atara Biotherapeutics in a research note issued to investors on Wednesday, January 22nd. HC Wainwright analyst R. Burns forecasts that the ...

Atara Biotherapeutics (NASDAQ:ATRA – Get Free Report)‘s stock had its “neutral” rating reiterated by analysts at HC ...

H.C. Wainwright analyst Robert Burns has reiterated their neutral stance on ATRA stock, giving a Hold rating yesterday.Invest with Confidence: ...

Atara Biotherapeutics (ATRA) stock slips as company faces an FDA clinical hold after rejection of lead candidate Ebvallo.

After receiving a complete response letter last week, the other shoe has dropped for Atara Biotherapeutics and its pipeline ...

Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer ...